Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel

Journal of Hematotherapy and Stem Cell Research

Volumn 9, Issue 6, 2000, Pages 855-860

  Fleming, D R ^a   Goldsmith, J ^a   Goldsmith, G H ^a   Stevens, D A ^a   Herzig, R H ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; MYELOABLATIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ADVANCED CANCER; APHERESIS; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MYALGIA; NEUTROPENIA; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0034490126     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581600750062282     Document Type: Article

References (21)

1. Re-establishing hematopoiesis after dose-intensive therapy with peripheral stem cells
2. Rapid and complete hemapoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high-dose chemotherapy?
3. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistance hematologic malignancy
4. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
5. Peripheral blood stem cells (PBSC's) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation
6. Optimization of peripheral blood stem cell collection
7. 2) and granulocyte colony stimulating factor in patients with multiple myeloma
8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: A pilot trial
9. The significance of CD34 quantitation in autologous bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT)
10. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering
11. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
12. Phase III randomized trials of docetaxel in patients with metastatic breast cancer
13. Doxetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience
14. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor
15. 2 of CY
16. + peripheral blood progenitor cells (PBPC) in patients with responding metastatic breast cancer
17. Effect of a new anticancer drug, docetaxel (RP56976) on human leukemia cell lines
18. Phase II trial of doxetaxel in non-Hodgkin's lymphomas: A study of the cancer and leukemia group B
19. In vitro cytotoxicity of docetaxel in childhood acute leukemias